Aethlon Medical is a San Diego clinical-stage device company with a single investigational product, the Hemopurifier, an extracorporeal cartridge that runs a patient's plasma over a plant-lectin resin to strip out enveloped viruses and tumor-derived extracellular vesicles. It has no approved product, no revenue, and an active cancer trial still in its dose-escalation phase. That is the business. The reportable event of this fiscal year is different: Aethlon lost $7.2 million on a compressed cost base, ended the year with about $5.1 million of cash, raised another roughly $5 million across two post-year-end financings, and - in the week after this annual report was filed - executed its third reverse stock split in fourteen months.
The count matters. Aethlon has now combined 1-for-8, 1-for-10, and 1-for-5 reverse splits since June 2025 - a combined 1-for-400 compression of the share count on top of serial dilutive offerings. At a reference price of $3.18 (August 11, 2026, on roughly 650,000 post-split shares), the market capitalizes the company near $2 million, against a cash balance the balance sheet and the disclosed post-year-end raises put in the neighborhood of $9–10 million. Strip the cash out and the enterprise value is deeply negative: the market is assigning the entire operating effort a negative price on top of the cash it holds. That is the Aclarion trade repeated - a cash pile offered below its own book value because the market does not yet believe the underlying therapeutic will ever earn entry.
Two things keep the story alive. The Australian oncology study - the reason the company exists - has completed its first two dosing cohorts, the Data Safety Monitoring Board cleared advancement into the third and final cohort, and the first Cohort 3 participant completed three week-long Hemopurifier sessions without device deficiencies or immediate complications. And the cash, whatever its origin in repeated reverse-split-and-raise cycles, is real and currently dominant relative to the market value. The thesis is not that the device works - no one has shown that yet - but that the market has priced the whole thing at less than the cash, with a live clinical program attached for free.